Positron emission tomography (PET) has identified lower GABAA receptor levels in the limbic system, including the nucleus accumbens, amygdala, and hippocampus, in high-functioning adult ASD patients compared to healthy controls (55, 127)
In 2010, taVNS was approved in Europe for the treatment of epilepsy and depression, and in 2012, it was approved for the treatment of pain (117, 118)
Studies demonstrate that GLP-1RAs, especially liraglutide and exenatide, consistently promote weight reduction and improve lipid profiles, which are critical for managing obesity and MetS, common in PCOS patients
FDA FDA is a regulatory agency responsible for monitoring anything they choose if it is being used for medicinal purposes
Plan durations vary by medication type and include 3-, 6-, 10-, or 12-month options